Jonathan M. Miller
Jonathan M. Miller has a total of 13 co-authors. Here are the top co-authors by number of shared publications:
Anthony C. Blackburn
Pharmaceutical Research and Development, World Wide Pharmaceutical Sciences, Pfizer Global Research and Development, Ann Arbor Laboratories, Ann Arbor, MichiganUSA
2 shared publicationsAndrew J. Melzak
Pharmaceutical Research and Development, World Wide Pharmaceutical Sciences, Pfizer Global Research and Development – Ann Arbor Laboratories, Ann Arbor, MI, USA
1 shared publicationAshlesh Sheth
Pfizer Global Research and Development
1 shared publication- Benjamin M. Collman
Pfizer Global Research & Development, Eastern Point Road, Groton, CT, USA
1 shared publication David J.W. Grant
Department of Pharmaceutics, College of Pharmacy, University of Minnesota, Weaver-Densford Hall, 308 Harvard Street SE, Minneapolis, Minnesota, 55455-0343, USA
1 shared publicationHenry Y. Wang
1 shared publication
Latest Publications
- Open Access
- 1 September 2006
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 7 (3) , E70-E73
Estimation of intramolecular cyclization activation energies via isothermal gravimetric analysis: A technical note
Summary and Conclusion Isothermal gravimetric analysis was used to monitor the weight loss of 4 exploratory compounds as an indicator of their solid-state thermal stability. Data obtained from TGA were further processed via a model-free isoconversional method to estimate the activation energy values. These values ranged from 140 to 218 kJ/mol and were inversely related to their corresponding surface areas. Based on their activation energy values, the relative stability of these 4 exploratory compounds can be ranked as C>D>B>A and their formulation development activities can be prioritized.
- 1 September 2006
- Published by Springer Nature in AAPS PharmSciTech
- Vol. 7 (3) , E70-E73
Open AccessEstimation of intramolecular cyclization activation energies via isothermal gravimetric analysis: A technical note
Summary and Conclusion Isothermal gravimetric analysis was used to monitor the weight loss of 4 exploratory compounds as an indicator of their solid-state thermal stability. Data obtained from TGA were further processed via a model-free isoconversional method to estimate the activation energy values. These values ranged from 140 to 218 kJ/mol and were inversely related to their corresponding surface areas. Based on their activation energy values, the relative stability of these 4 exploratory compounds can be ranked as C>D>B>A and their formulation development activities can be prioritized.
- 1 January 2005
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 10 (2) , 291-297
Identifying the Stable Polymorph Early in the Drug Discovery–Development Process
The thermodynamically most stable polymorph under ambient conditions is almost without exception the most desirable crystalline form for development by a pharmaceutical company. It is, therefore, beneficial to discover and to characterize this polymorph at the earliest possible stage of development. A screen for discovering the stable polymorph of a pharmaceutical compound early in the drug discovery–development process is developed and described. In this screen, a small amount of compound is suspended in a diverse group of solvents for two weeks in an effort to crystallize the most stable polymorph. The solubility of the compound in each solvent utilized in the stable polymorph screen is also simultaneously determined using a simple gravimetric method. Ritonavir and an early development candidate (Pfizer compound A) are used as model compounds to demonstrate the utility of the screen for finding the stable polymorph early in the drug discovery–development process.
- 1 January 2005
- Published by Taylor & Francis in Pharmaceutical Development and Technology
- Vol. 10 (2) , 291-297
Identifying the Stable Polymorph Early in the Drug Discovery–Development Process
The thermodynamically most stable polymorph under ambient conditions is almost without exception the most desirable crystalline form for development by a pharmaceutical company. It is, therefore, beneficial to discover and to characterize this polymorph at the earliest possible stage of development. A screen for discovering the stable polymorph of a pharmaceutical compound early in the drug discovery–development process is developed and described. In this screen, a small amount of compound is suspended in a diverse group of solvents for two weeks in an effort to crystallize the most stable polymorph. The solubility of the compound in each solvent utilized in the stable polymorph screen is also simultaneously determined using a simple gravimetric method. Ritonavir and an early development candidate (Pfizer compound A) are used as model compounds to demonstrate the utility of the screen for finding the stable polymorph early in the drug discovery–development process.
- 1 April 2004
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 35 (1) , 65-73
Rapid estimation of kinetic parameters for thermal decomposition of penicillins by modulated thermogravimetric analysis
- 1 April 2004
- Published by Elsevier in Journal of Pharmaceutical and Biomedical Analysis
- Vol. 35 (1) , 65-73
Rapid estimation of kinetic parameters for thermal decomposition of penicillins by modulated thermogravimetric analysis
- 1 September 2002
- Published by Wiley in Electrophoresis
- Vol. 23 (17) , 2833-2841
Semi-empirical relationships between effective mobility, charge, and molecular weight of pharmaceuticals by pressure-assisted capillary electrophoresis: Applications in drug discovery
Relationships between effective mobility (meff), calculated charge (Zc), and molecular weight (MW) are semi‐empirically derived for pharmaceuticals using pressure‐assisted capillary electrophoresis (PACE). We determined the meff at 12 different pH points (2.0–11.4) of 66 pharmaceutical‐like compounds ranging in MW from 79 to 825 g/mol. Plots of the observed meff values versusZc/MWx (where x is a fractional coefficient) gave linear relationships. For anions, it was found that the best correlation (R2 = 0.9666) exists when the fractional coefficient is equal to 0.4920, resulting in the equation meff = 0.1853 (Zc/MW0.4920). For cations, the best linear relationship (R2 = 0.9861) gave the equation meff = 0.3888 (Zc/MW0.6330). The meff, Zc/MWx relationships were then applied to: (i) developing a technique for selecting an appropriate pH to achieve optimal separation of pharmaceuticals and (ii) determining the maximum charge of a molecule in the pH range of determination of negative log of the dissociation constants (pKa) by PACE, thus enabling the correct choice of model equation to be automated without structure analysis.
- 1 September 2002
- Published by Wiley in Electrophoresis
- Vol. 23 (17) , 2833-2841
Semi-empirical relationships between effective mobility, charge, and molecular weight of pharmaceuticals by pressure-assisted capillary electrophoresis: Applications in drug discovery
Relationships between effective mobility (meff), calculated charge (Zc), and molecular weight (MW) are semi‐empirically derived for pharmaceuticals using pressure‐assisted capillary electrophoresis (PACE). We determined the meff at 12 different pH points (2.0–11.4) of 66 pharmaceutical‐like compounds ranging in MW from 79 to 825 g/mol. Plots of the observed meff values versusZc/MWx (where x is a fractional coefficient) gave linear relationships. For anions, it was found that the best correlation (R2 = 0.9666) exists when the fractional coefficient is equal to 0.4920, resulting in the equation meff = 0.1853 (Zc/MW0.4920). For cations, the best linear relationship (R2 = 0.9861) gave the equation meff = 0.3888 (Zc/MW0.6330). The meff, Zc/MWx relationships were then applied to: (i) developing a technique for selecting an appropriate pH to achieve optimal separation of pharmaceuticals and (ii) determining the maximum charge of a molecule in the pH range of determination of negative log of the dissociation constants (pKa) by PACE, thus enabling the correct choice of model equation to be automated without structure analysis.